Assess whether to resubmit, meet, or pause the program (6c4651)

SITUATION Pharmacovigilance medical reviewer owns this CMC and Development Pathways review in a mid-size sponsor after a complete response letter. An AdCom briefing document that overstates subgroup findings is the triggering event; phase-3 protocol with endpoint-sensitivity issues is the evidence for whether to resubmit, meet, or pause the program.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using phase-3 protocol with endpoint-sensitivity issues after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Phase-3 protocol with endpoint-sensitivity issues reads as To resubmit, meet, once an AdCom briefing document that overstates subgroup findings is lined up to the same Pharma & Life Sciences population. 2. Phase-3 protocol with endpoint-sensitivity issues is closer to Pause the program after an AdCom briefing document that overstates subgroup findings; To resubmit, meet, would over-claim this CMC and Development Pathways extract. 3. A dual reading is still live in phase-3 protocol with endpoint-sensitivity issues for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. 4. Phase-3 protocol with endpoint-sensitivity issues is missing the fact pharmacovigilance medical reviewer needs after an AdCom briefing document that overstates subgroup findings; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after an AdCom briefing document that overstates subgroup findings). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - Named option among To resubmit, meet,, Pause the program and the fact that kills the others - Owner and next date for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter